Skip to main content
. 2017 Feb 15;20(4):295–304. doi: 10.1093/ijnp/pyw116

Table 3.

Injection Site Treatment-Emergent Adverse Events

Single-Dose Study Multiple-Dose Study
Injection Site Adverse Events, n (%) Deltoid (n = 17) Gluteal (n = 18) Total
(n = 138)
Pain 6 (35.3) 5 (27.8) 38 (27.5)
Rash 1 (5.9) 0 0
Erythema 0 0 1 (0.7)
Induration 0 0 1 (0.7)
Swelling 0 0 1 (0.7)